WeConnectPatients.com · Nerve & Immune Health
Your body is attacking your own nerves. Understanding why is the first step to doing something about it.
CIDP isn’t just “tingling.” It’s your immune system slowly stripping the protective coating off your nerves. It’s real, it’s progressive, and it’s treatable. Here’s what you need to know.
Per 100,000
CIDP is rare — but very real for the people living with it
Diagnostic Delay
Most people wait years to get the right diagnosis
Respond to IVIG
First-line immunoglobulin therapy helps the majority
May Need Mobility Support
Without treatment, significant disability can develop — underscoring the importance of early diagnosis and treatment
Your immune system is attacking the protective coating around your nerves. That’s what CIDP is.
It’s not in your head. It’s not just getting older. And it’s not something you should push through. CIDP is a real autoimmune condition — and the sooner you understand it, the sooner you can fight back.
CIDP stands for chronic inflammatory demyelinating polyneuropathy. That’s a mouthful. Here’s what it means: your immune system is mistakenly destroying the myelin sheath — the insulating layer around your peripheral nerves. Without that coating, your nerves can’t send signals properly.
The result is weakness that builds slowly. First your legs feel heavy. Then climbing stairs gets hard. Then your hands stop cooperating. It usually develops over eight weeks or more, which is one reason it takes so long to diagnose. It creeps.
An estimated 40,000 to 80,000 people in the U.S. have CIDP. It can strike at any age, but peaks in the 40s–50s and again in the 60s–70s. People assigned male at birth are slightly more likely to develop CIDP, though it affects people of all genders. It’s rare — but for the people living with it, it’s anything but invisible.
The good news: CIDP responds to treatment. The majority of people improve significantly with the right therapy. But early diagnosis matters. Published estimates suggest that without treatment, 20–30% of people may need mobility support such as a wheelchair. That’s not a scare tactic — it’s why getting answers matters.
What drives CIDP
CIDP is driven by your immune system. But several factors influence who gets it and how it behaves.
Your immune system
In CIDP, your immune system mistakes the myelin sheath around your nerves for a threat and attacks it. This slows or blocks nerve signals. The damage is gradual — which is why symptoms build over weeks and months, not hours.
Nerve damage pattern
CIDP typically affects both sides of the body symmetrically. It targets both proximal muscles (near your trunk) and distal muscles (hands, feet). This pattern is one of the key features that helps distinguish it from other neuropathies.
Autoimmune connection
Some people with CIDP have other autoimmune conditions. Having one autoimmune disorder can increase your risk of developing another. Diabetes and HIV can also present with CIDP-like symptoms, which complicates diagnosis.
Who gets it
CIDP can appear at any age, but it peaks in two windows: the 40s–50s and the 60s–70s. People assigned male at birth are slightly more likely to develop it. There are no known environmental triggers — you didn’t do anything to cause this.
Variants exist
Not everyone with CIDP looks the same. About 50–60% have “typical” CIDP with symmetrical weakness and both motor and sensory involvement. The rest have atypical variants — some predominantly sensory, some asymmetric, some affecting only specific nerve groups. This variability is another reason it gets missed.
How CIDP is diagnosed
Getting a CIDP diagnosis is rarely fast. Most people wait one to three years from their first symptom — and for those with limited access to specialist care, the wait can be longer. If your symptoms are being dismissed or you’re not getting answers, asking for a referral to a neuromuscular specialist is a reasonable and appropriate step.
Clinical evaluation
Your neurologist will test your strength, reflexes, and sensation. The hallmark finding is reduced or absent reflexes combined with weakness in both proximal and distal muscles — legs and arms, near and far from your trunk.
Nerve conduction studies
Electromyography (EMG) and nerve conduction studies are the backbone of CIDP diagnosis. These tests measure how fast and how reliably your nerves transmit signals. When signals slow down significantly (called slowed conduction velocity) or stop partway along the nerve (called a conduction block), it points to damage to the myelin sheath — the signature of CIDP.
Ruling out mimics
CIDP overlaps with many other conditions, including Guillain-Barré syndrome (a related but usually short-term nerve condition), hereditary neuropathies, and amyloidosis. Your doctor may order blood work, genetic tests, or a spinal fluid analysis (which often shows elevated protein) to narrow it down.
Advanced imaging
MRI of the spine and peripheral nerves can show nerve enlargement or inflammation. This is increasingly useful, especially in atypical cases where the nerve conduction results are borderline.
No single test confirms CIDP
Doctors diagnose it by ruling out other conditions and recognizing a pattern of findings across tests. This is what clinicians call a “diagnosis of exclusion.” It’s one reason the process takes time, and why seeing a specialist in neuromuscular conditions matters.
Treatment has come a long way
CIDP is treatable. Most people respond to first-line therapy, and treatment has come a long way.
First Line
Immunoglobulin Therapy (IVIG/SCIg)
The backbone of CIDP treatment. Intravenous immunoglobulin (IVIG) delivers concentrated antibodies through an IV infusion, modulating your immune system’s attack on your nerves. Published data suggest 60–80% of patients respond. Subcutaneous immunoglobulin (SCIg) offers a home-based alternative for many patients.
Alternative First Line
Plasma Exchange
Physically removes the harmful antibodies from your blood. Published studies suggest 65–85% of patients respond, often with faster initial improvement than IVIG — though plasma exchange typically provides short-term benefit and is often combined with other therapies for sustained management.
Established Option
Corticosteroids
Corticosteroids reduce inflammation broadly and can be used alone as initial therapy or alongside IVIG or plasma exchange. They work, but long-term use carries real side effects — bone loss, weight gain, blood sugar changes. Most doctors try to taper them over time.
Research Frontier
Emerging Therapies
Scientists are testing new approaches: complement inhibitors, targeted immune modulators, and better ways to predict which patients will respond to which treatment. Clinical trials are where these options become available first.
All treatments carry potential side effects. IVIG can cause headaches and, rarely, kidney issues. Plasma exchange requires vascular access and carries infection risk. Talk to your neurologist about which risks and benefits apply to you.
“For the first time in years, I could get through a full day without dropping things. It wasn’t a cure — but it was real progress.”
Reflects common patient experiences
IVIG therapy is expensive — costs vary widely depending on dose, body weight, insurance coverage, and whether infusions are done in a hospital, infusion center, or at home. Most people need ongoing maintenance infusions. If cost is a barrier, ask about patient assistance programs. Some clinical trials provide medications at no cost.
Answers to common questions
Living with CIDP raises real, practical questions. Here are honest answers to some of the most common ones.
Will CIDP get worse over time?
It depends on your treatment. Without treatment, yes — CIDP is progressive. But with the right therapy, most people stabilize or improve. Some go into remission. The key is consistent treatment and regular monitoring.
How often will I need infusions?
It varies. Initial IVIG is typically given over 3–5 days, then maintenance infusions every 3–4 weeks. Some people need them more often, some less. Your neurologist will adjust the schedule based on how you respond.
Can I still work with CIDP?
Many people do. But published surveys suggest 40–50% of working-age patients report significant job limitations. Be honest with yourself and your employer. Occupational therapy can help you adapt. If you have an employer, workplace accommodations under the ADA are your legal right. If you are self-employed, freelance, or in a non-traditional work arrangement, an occupational therapist can still help you find ways to adapt your work environment and schedule.
What about the fatigue — and brain fog?
Both are real, and neither is laziness. CIDP fatigue is neurological — your nerves are working overtime to compensate for damaged pathways. Some people also notice difficulty concentrating or processing information more slowly. Pace yourself. Prioritize. And tell your doctor about all of it, because these symptoms should factor into your treatment plan.
Should I see a specialist?
Absolutely. CIDP requires a neurologist, ideally one specializing in neuromuscular disorders. Primary care doctors are great, but this condition needs someone who sees it regularly. Ask for a referral if you don’t have one.
Does CIDP affect mental health?
Yes, it can. Living with a rare, chronic, progressive nerve condition takes a psychological toll. Anxiety about the future, frustration with the diagnostic journey, grief over lost abilities — all of it is real. Talk to someone. Mental health support is part of your care.
What about my family and caregivers?
CIDP doesn’t just affect you. Partners, parents, and children often take on caregiving roles — and that comes with its own stress. Support groups like the GBS|CIDP Foundation offer resources for both patients and caregivers.
Is there a cure?
Not yet. But treatments are effective, and research is advancing. Some patients achieve long-term remission — meaning their symptoms are controlled to the point where active treatment may not be needed for a period of time. The goal right now is keeping you functional, independent, and as symptom-free as possible while science works toward better answers.
Research & Progress
The science is moving fast
CIDP research is accelerating. Scientists now understand much more about the specific immune pathways involved in nerve damage, and that knowledge is driving a new generation of targeted therapies.
What’s in the pipeline: complement inhibitors that could block the immune attack more precisely. Biomarker-driven approaches under study aim to help predict which patients are most likely to respond to specific treatments — potentially reducing the trial-and-error that many patients currently experience. And expanded home-based infusion options that could make ongoing treatment less disruptive to your life.
Clinical trials are how these treatments get tested and eventually become available. Participating gives you access to specialized care teams and emerging therapies while contributing to the future of CIDP treatment. No obligation. Your choice. Your standard care continues either way.
You’ve waited long enough for answers. Now find the right next step.
Clinical research for CIDP is opening new doors. Whether you were just diagnosed or have been managing this for years, there may be options worth exploring.
Not sure where to start?
Walking into a neurology appointment with the right questions changes everything. We put together a quick guide.
This content is for educational purposes only and isn’t a substitute for medical advice. Talk to your healthcare provider before making decisions about your care. Information about clinical trials is for general awareness, not an endorsement of any specific study.
Sources: GBS|CIDP Foundation International, NINDS, EAN/PNS, Mayo Clinic, Cleveland Clinic, peer-reviewed literature (2019–2025), ClinicalTrials.gov.
WeConnect is a Takeda initiative connecting people to clinical trial opportunities. Visit WeConnectPatients.com.